×

Fortimedix Surgical Announces the U.S. Launch of symphonX™ Surgical Platform, the World’s Lowest Profile Single-Port Surgery Solution, During American College of Surgeons (ACS) Clinical Congress 2016; Innovative technology addresses unmet needs in sing

NUTH, The Netherlands, and SAN DIEGO, Oct. 17, 2016 (GLOBE NEWSWIRE) -- Fortimedix Surgical today announced the official launch in the U.S. of symphonX™, the world’s first single-port surgery solution that is compatible with a standard 15mm trocar for use in minimally invasive abdominal laparoscopic surgery, during the American College of Surgeons (ACS) Clinical Congress. The launch event will be held on Tuesday October 18, 2016 at 3pm EDT at Fortimedix Surgical’s booth, #1139, and will feature a presentation by world-renowned surgeon, Santiago Horgan, MD, professor of surgery and chief of minimally invasive surgery at UC San Diego Health.

“We are thrilled to formally launch the symphonX™ Surgical Platform in the U.S., which we believe has the potential to deliver on the promise of single-port surgery and elevate the standard of care in laparoscopy,” said Tom Dempsey, VP Sales of Fortimedix Surgical. “The technology was developed under the engineering code name FMX314 in close collaboration with leading surgeons to ensure that the platform addresses the needs of the medical community, and by extension the patient community. Our early clinical experience underlines its potential for improved patient satisfaction and health outcomes, including fewer port-site complications, less post-operative pain, faster recovery and exceptional cosmesis.”

symphonX™ addresses unmet needs in minimally invasive surgery by providing the medical community with a surgical solution that is small, simple and secure. Emulating conventional, multi-port laparoscopy, makes symphonX™ easy to use and enables surgeons to perform procedural steps ergonomically, allowing for a comfortable and secure single-port approach.

The first two U.S. commercial procedures with symphonX™ were recently performed at UC San Diego Health by Dr. Horgan, following 510(k) clearance in the U.S. and CE Mark approval in Europe. The European commercial launch is planned for 2017. For more information, visit www.fortimedixsurgical.com.

About Fortimedix Surgical
Fortimedix Surgical is a fast growing medical device company, aiming to challenge the status quo in minimally invasive surgery by creating novel devices that capture the claimed benefits of single-port surgery. The company is headquartered in Nuth, The Netherlands, and has a U.S. subsidiary in San Diego, CA. With a strong history as a global market leader in contract stent manufacturing, Fortimedix has been a trusted partner in the medical device industry for over 15 years. Fortimedix Surgical is committed to driving the evolution of minimally invasive surgery through smart innovation across surgical specialties to improve the quality of life of patients throughout the world.

For more information, please visit www.fortimedixsurgical.com

Forward-Looking Statements
Certain statements herein include “forward-looking” statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the use of forward-looking terminology, such as “may,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe,” “project” or “continue” or the negative thereof or other similar words. All forward looking statements involve risks and uncertainties, including, but not limited to, the protection of intellectual property, changes to governmental regulation of medical devices, the introduction of new products into the marketplace by competitors, changes to the competitive environment, the acceptance of new products in the marketplace, conditions of the surgical industry and economic and political conditions globally. Actual results may differ materially from those contemplated or implied by the forward-looking statements. The forward-looking statements speak only as of the date of this release and Fortimedix Surgical assumes no duty to update them to reflect new, changing or unanticipated events or circumstances.

For media inquiries, please contact:

Fortimedix Surgical B.V., Monique Biermans, m.biermans@fortimedix.com, +31 (0)6 24 676 376
Digital press release available at: www.fortimedixsurgical.com/news-events

Lazar Partners, Chantal Beaudry, cbeaudry@lazarpartners.com, or Amy Feldman,
afeldman@lazarpartners.com, +1 (212) 867-1762


Source:Fortimedix Surgical B.V.